PharmaTimes

Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis

EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA ...
Business Insider

EQS-Adhoc: PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults

PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults 27-Jan-2023 / 12:59 CET/CEST Disclosure of an inside ...
manilatimes

TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor

Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and intravenous induction options inulcerative colitis, providing flexibility and simplicity for patients ...
PharmiWeb

PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults

Aachen (Germany), 27 January 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Medicines ...